An analysis examining Medicare data found that the number of elderly beneficiaries receiving narcotic painkillers and anti-anxiety medications drastically increased from 2007 to 2012.
An analysis examining Medicare data found that the number of elderly beneficiaries receiving narcotic painkillers and anti-anxiety medications drastically increased from 2007 to 2012. Those patients were also found to be taking medications for much longer periods of time than other patients.
To be exact, 8.5 million patients aged 65 years and older received prescriptions under Medicare for opioid pain medications—a 30% increase over 5 years. As well, the use of drugs like hydrocodone and oxycodone grew more than 50%, while the amount of each narcotic provided to the average beneficiary rose 15% to about 3 months’ supply. The data suggests that nearly 1 in 5 Medicare beneficiaries is using the drugs for pain management on a long-term basis.
“The big surprise for me is the amount of time that people are being left on these drugs—it’s really concerning,” said Linda Simoni-Wastila, BSPharm, PhD, professor at the University of Maryland School of Pharmacy.
The number of senior patients who were prescribed anti-anxiety medications, including alprazolam and buspirone, also rose by 25% to 700,000 beneficiaries. They received an average of 5 months’ supply of the medications in 2012—a 10% increase from 2007.
The statistics are concerning for public health officials, as the long-term use of pain and antianxiety medications can put patients at risk for abuse or dependence.
Officials from CMS said, “Medicare takes instances of prescription drug misuse very seriously and recently put in place aggressive new rules that take further steps to prevent drug abuse and overutilization.”
Around the Web
Seniors' Use of Potent Meds via Medicare Staggering [USA Today]
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More